CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis

Triple-negative breast cancer (TNBC) has a poor prognosis due to the lack of specific therapeutic targets. CCT020312, a selective eukaryotic translation initiation factor 2 alpha (eIF2α)/protein kinase RNA-like endoplasmic reticulum kinase (PERK) activator, may have a potent anti-tumor effect. In th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Li, Xiaoli, Yu, Xiaoping, Zhou, Duanfang, Chen, Bo, Li, Wenjun, Zheng, Xiangru, Zeng, Hongfang, Long, Liangyuan, Zhou, Weiying
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7250150/
https://ncbi.nlm.nih.gov/pubmed/32508655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00737
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados